179 related articles for article (PubMed ID: 14970225)
1. Structure-function analysis of the reactive site in the first Kunitz-type domain of human tissue factor pathway inhibitor-2.
Chand HS; Schmidt AE; Bajaj SP; Kisiel W
J Biol Chem; 2004 Apr; 279(17):17500-7. PubMed ID: 14970225
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of Kunitz domain 1 (KD1) of tissue factor pathway inhibitor-2 in complex with trypsin. Implications for KD1 specificity of inhibition.
Schmidt AE; Chand HS; Cascio D; Kisiel W; Bajaj SP
J Biol Chem; 2005 Jul; 280(30):27832-8. PubMed ID: 15932872
[TBL] [Abstract][Full Text] [Related]
3. Engineering kunitz domain 1 (KD1) of human tissue factor pathway inhibitor-2 to selectively inhibit fibrinolysis: properties of KD1-L17R variant.
Bajaj MS; Ogueli GI; Kumar Y; Vadivel K; Lawson G; Shanker S; Schmidt AE; Bajaj SP
J Biol Chem; 2011 Feb; 286(6):4329-40. PubMed ID: 21115497
[TBL] [Abstract][Full Text] [Related]
4. Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1.
Kirchhofer D; Peek M; Li W; Stamos J; Eigenbrot C; Kadkhodayan S; Elliott JM; Corpuz RT; Lazarus RA; Moran P
J Biol Chem; 2003 Sep; 278(38):36341-9. PubMed ID: 12815039
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory properties of human recombinant Arg24-->Gln type-2 tissue factor pathway inhibitor (R24Q TFPI-2).
Kamei S; Petersen LC; Sprecher CA; Foster DC; Kisiel W
Thromb Res; 1999 May; 94(3):147-52. PubMed ID: 10326761
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor.
Petersen LC; Bjørn SE; Olsen OH; Nordfang O; Norris F; Norris K
Eur J Biochem; 1996 Jan; 235(1-2):310-6. PubMed ID: 8631347
[TBL] [Abstract][Full Text] [Related]
7. Molecular cloning, expression, and characterization of bovine tissue factor pathway inhibitor-2.
Du X; Deng FM; Chand HS; Kisiel W
Arch Biochem Biophys; 2003 Sep; 417(1):96-104. PubMed ID: 12921785
[TBL] [Abstract][Full Text] [Related]
8. Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system.
Rester U; Bode W; Moser M; Parry MA; Huber R; Auerswald E
J Mol Biol; 1999 Oct; 293(1):93-106. PubMed ID: 10512718
[TBL] [Abstract][Full Text] [Related]
9. A spider-derived Kunitz-type serine protease inhibitor that acts as a plasmin inhibitor and an elastase inhibitor.
Wan H; Lee KS; Kim BY; Zou FM; Yoon HJ; Je YH; Li J; Jin BR
PLoS One; 2013; 8(1):e53343. PubMed ID: 23308198
[TBL] [Abstract][Full Text] [Related]
10. Expression and characterization of the first kunitz domain of human tissue factor pathway inhibitor-2.
Kong D; Ma D; Bai H; Guo H; Cai X; Mo W; Tang Q; Song H
Biochem Biophys Res Commun; 2004 Nov; 324(4):1179-85. PubMed ID: 15504338
[TBL] [Abstract][Full Text] [Related]
11. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin.
Liu Y; Stack SM; Lakka SS; Khan AJ; Woodley DT; Rao JS; Rao CN
Arch Biochem Biophys; 1999 Oct; 370(1):112-8. PubMed ID: 10496984
[TBL] [Abstract][Full Text] [Related]
12. Replacement of lysine by arginine, phenylalanine and tryptophan in the reactive site of the bovine trypsin-kallikrein inhibitor (Kunitz) and change of the inhibitory properties.
Jering H; Tschesche H
Eur J Biochem; 1976 Jan; 61(2):453-63. PubMed ID: 129327
[TBL] [Abstract][Full Text] [Related]
13. Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein.
Chen VC; Chao L; Chao J
J Biol Chem; 2000 Dec; 275(49):38457-66. PubMed ID: 10993887
[TBL] [Abstract][Full Text] [Related]
14. S2'-subsite variations between human and mouse enzymes (plasmin, factor XIa, kallikrein) elucidate inhibition differences by tissue factor pathway inhibitor -2 domain1-wild-type, Leu17Arg-mutant and aprotinin.
Vadivel K; Kumar Y; Ogueli GI; Ponnuraj SM; Wongkongkathep P; Loo JA; Bajaj MS; Bajaj SP
J Thromb Haemost; 2016 Dec; 14(12):2509-2523. PubMed ID: 27797450
[TBL] [Abstract][Full Text] [Related]
15. Decoy plasminogen receptor containing a selective Kunitz-inhibitory domain.
Kumar Y; Vadivel K; Schmidt AE; Ogueli GI; Ponnuraj SM; Rannulu N; Loo JA; Bajaj MS; Bajaj SP
Biochemistry; 2014 Jan; 53(3):505-17. PubMed ID: 24383758
[TBL] [Abstract][Full Text] [Related]
16. Acid-stable trypsin-plasmin inhibitors formed enzymatically from plasma precursor protein.
Sumi H; Yoshida E; Hamada H; Mihara H
Biochim Biophys Acta; 1988 Jul; 966(1):1-11. PubMed ID: 2968815
[TBL] [Abstract][Full Text] [Related]
17. The hydrogen bonds between Arg423 and Glu472 and other key residues, Asp443, Ser477, and Pro489, are responsible for the formation and a different positioning of TNP-ATP and ATP within the nucleotide-binding site of Na(+)/K(+)-ATPase.
Lánský Z; Kubala M; Ettrich R; Kutý M; Plásek J; Teisinger J; Schoner W; Amler E
Biochemistry; 2004 Jul; 43(26):8303-11. PubMed ID: 15222743
[TBL] [Abstract][Full Text] [Related]
18. The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa.
Burgering MJ; Orbons LP; van der Doelen A; Mulders J; Theunissen HJ; Grootenhuis PD; Bode W; Huber R; Stubbs MT
J Mol Biol; 1997 Jun; 269(3):395-407. PubMed ID: 9199408
[TBL] [Abstract][Full Text] [Related]
19. Atypical Kunitz-type serine proteinase inhibitors produced by the ruminant placenta.
MacLean JA; Roberts RM; Green JA
Biol Reprod; 2004 Aug; 71(2):455-63. PubMed ID: 15070828
[TBL] [Abstract][Full Text] [Related]
20. Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant.
Zhang E; St Charles R; Tulinsky A
J Mol Biol; 1999 Feb; 285(5):2089-104. PubMed ID: 9925787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
